References
- CastelliWPGarrisonRJWilsonPWFIncidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham StudyJAMA1986256283528383773200
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive Summary of the Third Report of the National Cholesterol Education Program (Adult Treatment Panel III)JAMA20012852486249711368702
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation20021063143342112485966
- CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med20043501495150415007110
- LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med20053521425143515755765
- PedersenTRFaergemanOKasteleinJJHigh dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trialJAMA20052942437244516287954
- GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation200411022723915249516
- GrundySMStatin trials and goals of cholesterol-lowering therapyCirculation199897143614399576422
- DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPSJAMA1998279161516229613910
- ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemiaN Engl J Med1995333130113077566020
- HaywardRAHoferTPVijanSNarrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problemAnn Intern Med200614552053017015870
- TabasIWilliamsKJBorenJSubendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implicationsCirculation20071161832184417938300
- KoschinskyMLMarcovinaSMBallantyneCMClinical Lipidology: A Companion to Braunwald’s Heart DiseasePhiladelphiaSaunders Elsevier2009130143
- GrundySMAtherogenic dyslipidemia associated with metabolic syndrome and insulin resistanceClin Cornerstone20068Suppl 1S21S2716903166
- CastelliWPCholesterol and lipids in the risk of coronary heart disease-the Framingham Heart StudyCan J Cardiol19884Suppl A5A10A3282627
- CastelliWPEpidemiology of triglycerides: a view from FraminghamAm J Cardiol1992703H9H
- GordonDJProbstfieldJLGarrisonRJHigh density lipoprotein cholesterol and cardiovascular disease. Four prospective American studiesCirculation1989798152642759
- HokansonJEAustinMATriglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein: a meta-analysis of population-based prospective studiesJ Cardiovasc Risk199632132198836866
- YarnellJWGPattersonCCSweetnamPMDo total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart diseaseArterioscler Thromb Vasc Biol2001211340134511498463
- JeppesenJHeinHOSuadicaniPGyntelbergFClinical investigation and reports: Triglyceride concentration and ischemia heart disease. An eight-year follow-up in the Copenhagen Male StudyCirculation199897102910369531248
- AssmannGSchulteHEckardsteinAHypertriglyceridemia and elevated lipoprotein(a) are are risk factors for major coronary events in middle-aged menAm J Cardiol199677117911848651092
- GenestJJMartin-MunleySSMcNamaraJRFamilial lipoprotein disorders in patients with premature coronary artery diseaseCirculation199285202520331534286
- GenestJJMcNamaraJRSalemDNShaeferEJPrevalence of risk factors in men with premature coronary artery diseaseAm J Cardiol199167118511892035438
- GordonTCastelliWPHjortlandMCHigh density lipoprotein as a protective factor against coronary heart disease. The Framingham StudyAm J Med197762707714193398
- LiuJSemposCTDonahueRPNon-high density lipoprotein and very low density lipoprotein cholesterol and their risk predictive values in coronary heart diseaseAm J Cardiol2006981363136817134630
- FrickMHEloMOHappaKHelsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart diseaseN Engl J Med1987317123712453313041
- HaimMBenderlyMBrunnerDElevated serum triglyceride levels in patients with coronary heart disease: The bezafibrate Infarction Prevention (BIP) RegistryCirculation199910047548210430760
- CarlsonLARosenhanerGReduction of mortality in the in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acidActa Med Scand19882234054183287837
- RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low high-density cholesterolN Engl J Med199934141041810438259
- KeechASimesRJBarterPThe Field Study InvestigatorsEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised control trialLancet20053661849186116310551
- The “Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus” an NIH study with support from multiple industry partners was just published (Effects of Combination Therapy in Type 2 Diabetes Mellitus. The ACCORD Study GroupN Engl J of Med3142010, and updated on March 18, 2010, at NEJM.org (10.1056/NEJMoa1001282).
- SuperkoHRKingSIIIIs lowering low-density lipoprotein an effective strategy to reduce cardiac riskCirculation200811756056818227396
- StaelasBDallongvilleJAuwerxJMechanism of action of fibrates on lipid and lipoprotein metabolismCirculation199898208820939808609
- BergerJMoellerDThe mechanisms of action of PPARsAnnu Rev Med20025340943511818483
- StaelsBAuwerxJRegulation of apoA-1 gene expression by fibratesAtherosclerosis1998Suppl 137S19S239694537
- ChinettiGLastavelSBockerVPPAR-alpha and PPAR gamma activators induce cholesterol removal from human macrophages from cells through stimulation of the ABCA1 pathwayNat Med20017535811135616
- MarxNSukhovaGKCollinsTPPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cellsCirculation1999993125313110377075
- MarxNMackmanNSchonbeckUPPAR alpha agonists inhibit tissue factor expression in human monocytes and macrophagesCirculation200110321321911208679
- JonesPHFibratesBallantyneCMClinical Lipidology: A Companion to Braunwald’s Heart DiseasePhiladelphiaSaunders Elsevier2009315325
- MuhlesteinJBMayHTJensenJRThe reduction of inflammatory biomarkers by statin, fibrate and combination therapy among diabetic patients with mixed dyslipidemia. The DIACOR (Diabetes and Combined Lipid Therapy Regimen) studyJ Am Coll Cardiol20064839640116843192
- KohKKHanSHQuonMJBeneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemiaDiabetes Care2005281419142415920062
- WysockiJBelowskiDKalinaMEffects of micronized fenofibrate on insulin resistance in patients with metabolic syndromeInt J Clin Pharmacol Ther20044221221715124979
- EllenRLBMcPhersonRLong-term efficacy and safety of fenofibrate and a statin in the treatment of combination hyperlipidemiaAm J Cardiol1998814A60B65B
- GrundySMVegaGLYuanZEffectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The Safari Trial)Am J Cardiol20059546246815695129
- DavidsonMHArmaniAMcKenneyJMSafety considerations with fibrate therapyAm J Cardiol2007Suppl 993C18C
- FarnierMFreemanMWMacdonellGEfficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemiaEur Heart J20052689790515781429
- FarnierMRothEGil-ExtremeraBEfficacy and safety of the coadministration ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemiaAm Heart J2007153335.e1335e817239698
- RizosEBiaraktariEGanotakisEEffect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymesJ Cardiovasc Pharmacol Ther2002721922612490967
- KeechASimesRJBarterPEffects of long-term fenofibrate therapy on cardiovascular events 9795 people with type II diabetes mellitus (the FIELD study): Randomized control trialLancet20053661849186116310551
- HottelartCEl EsperNRoseFFenofibrate increased creatinemia by increasing metabolic production of creatinineNephron20029253612372935
- TsimihodimosVMiltiadousGBairaktariEElisafMPossible mechanisms of the fibrate-induced increase in serum creatinineClin Nephrol20025740740812036205
- TonelliMCollinsDRobinsSEffect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary diseaseAm J Kidney Dis20044483283915492949
- AnsquenJCFoucherCRattierSFenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in Type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)Am J Kidney Dis20054548549315754270
- MekkiesMSteinEKhouryPEffects of fenofibrate on lipids, lipoproteins and apolipoproteins in 33 subjects with primary hypercholesterolaemiaAtherosclerosis19876357643548734
- BradfordRGoldbergASchoenfeldGDouble-blind comparison of bezaf ibrate versus placebo in male volunteers with hyperlipoproteinemiaAtherosclerosis19929231401575820
- GottoAMBreenWJCordnerCNOnce-daily, extended-release gemfibrozil in patients with dyslipidemia. The Lopid SR Work Group IAm J Cardiol199371105710638475869
- ZimetbaumPFrishmanWHKahnSEffects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteinsJ Clin Pharmacol19913125372045526
- StaelsBDallongevilleJAuwerxJMechanism of action of fibrates on lipid and lipoprotein metabolismCirculation199898208820939808609
- LahdenperaSTilly-KiesiMVuorinen-MarkkolaHEffects of gemfibrozil on low-density lipoprotein particle size, density, distribution and composition in patients with type II diabetesDiabetes Care1993165845928462384
- KohKKQuonMJHanSHAdditive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemiaJ Am Coll Cardiol2005451649195315893182
- McKenneyJJonesMAbbySSafety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemiaCurr Med Res Opin2005211403141216197659
- Trilipix [package insert]North Chicago (IL)Abbott Laboratories2008
- JonesPHDavidsonMHReporting rate of rhabdomyolysis with fenofibrate + fibrates versus gemfibrozil + any statinAm J Cardiol20059512012215619408
- JonesPHBaysHEDavidsonMHEvaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statinsClin Drug Investig200828625634
- JonesPHDavidsonMHKashyapMLEfficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 studyAtherosclerosis200920420821518996523
- MohiuddinSMPepineCJKellyMTEfficacy and safety of ABT-335 fenofibric acid in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, control studyAm Heart J200915719520319081418
- GoldbergACBaysHEBallantyneCMEfficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemiaAm J Cardiol200910351552219195513
- BaysHEJonesPHMohiuddinSMLong-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemiaJ Clin Lipidol20082426435
- BrunzellJDDavidsonMFurbergCDLipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology FoundationDiabetes Care20083181182218375431